Parker‑Hannifin Announces $5.0B Revolving Credit Line; $2.0B Delayed‑Draw Loan

What Happened Parker‑Hannifin filed an 8‑K (Item 8.01) reporting that on September 4, 2026 it entered into a new revolving credit agreement increasing its total revolving credit line to $5.0 billion and authorized a matching $5.0 billion commercial paper program. The company also said it expects to enter a Three‑Year Delayed Draw Term Loan Agreement (the “CIRCOR Credit Agreement”) with U.S. Bank National Association as administrative agent providing up to $2.0 billion of delayed‑draw term loans to help finance its announced acquisition of CIRCOR’s Commercial and Defense Aerospace business (the CIRCOR Acquisition), which Parker‑Hannifin announced on May 21, 2026 (purchase price ~ $2.55 billion in cash).

Key Details

• New revolving credit agreement entered on September 4, 2026 increases the revolving line to $5.0 billion.
• Company authorized a corresponding increase of its commercial paper program to $5.0 billion (Sept 4, 2026).
• Parker‑Hannifin expects a Three‑Year Delayed‑Draw Term Loan facility of up to $2.0 billion (U.S. Bank as agent) to fund part of the CIRCOR Acquisition; permits one draw at closing and up to two additional draws after closing.
• The CIRCOR Acquisition and the CIRCOR Credit Agreement are subject to customary conditions and uncertainties; there is no assurance either transaction will close.

Why It Matters These actions increase Parker‑Hannifin’s short‑term liquidity and financing capacity, giving the company flexibility to support working capital, commercial paper issuance, and to help fund the intended CIRCOR acquisition. If the delayed‑draw loan is drawn, it would increase the company’s funded debt and could affect leverage and interest costs; conversely, the facility also provides ready financing for the planned cash acquisition or for general corporate uses, including potential repayment of existing debt. Investors should note the CIRCOR transaction and the loan remain subject to conditions and the company’s forward‑looking statements and risk factors disclosed in its Form 10‑K.